Serum ferritin, transferrin and metabolic syndrome are risk factors for subclinical atherosclerosis in Egyptian women with systemic lupus erythematosus (SLE)

被引:3
作者
El-Hady, Aliaa [1 ]
Sennara, Soha [2 ]
Mosaad, Yasmin [3 ]
Mahmoud, Nisreen [4 ]
机构
[1] Al Mataria Teaching Hosp, Rheumatol & Rehabil Dept, Cairo, Egypt
[2] Fayoum Univ, Fac Med, Rheumatol & Rehabil Dept, Faiyum, Egypt
[3] Al Mataria Teaching Hosp, Clin Pathol Dept, Cairo, Egypt
[4] Al Mataria Teaching Hosp, Diagnost Radiol Dept, Cairo, Egypt
关键词
Systemic lupus erythematosus; Metabolic syndrome; Serum ferritin; Carotid intima-media thickness; DISEASE-ACTIVITY; PREVALENCE; ASSOCIATION; BIOMARKERS; THICKNESS; CAPACITY; PROTEIN; OBESITY;
D O I
10.1016/j.ejr.2018.06.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim of the work: This work aimed to measure serum ferritin and transferrin levels and to study the presence of metabolic syndrome (MetS) in Egyptian systemic lupus erythematosus (SLE) females and to correlate them with disease activity, damage, clinical status and subclinical atherosclerosis. Patients and methods: The study included 50 SLE female patients and 25 matched control. SLE disease activity index (SLEDAI) and damage index (DI) were assessed and the presence of MetS determined. Serum ferritin was measured by enhanced chemi-luminescence and the carotid intima-media thickness (cIMT) was assessed by B-mode ultrasound. Results: The mean cIMT (0.71 +/- 0.14 mm) and ferritin (2098 +/- 132.99 ng/ml) were significantly higher in patients compared to controls (0.62 +/- 0.05 mm and 71.7 +/- 18.7 ng/ml; p = 0.003 and p < 0.001, respectively). 28% of patients and 12% controls had MetS. 6(12%) had a thickened cIMT (>= 0.9 mm), 3 of them had atherosclerotic plaques (>1.3 mm). The cIMT significantly correlated (p < 0.05) with age (r = 0.54), disease duration (r = 0.55), SLEDAI (r = 0.37), DI (r = 0.52), ferritin (r = 0.31), cholesterol (r = 0.32), triglycerides (r = 0.7), fasting blood sugar (r = 0.72), systolic (r = 0.68) and diastolic (r = 0.7) blood pressure and negatively with transferrin (r = -0.31), low (r = -0.32) and high-density lipoprotein (r = -0.53) and C3 (r = -0.66). Patients with MetS had significantly higher cIMT (0.9 +/- 0.3 mm) versus those without (0.64 +/- 0.1 mm)(p < 0.0001). Conclusion: MetS in SLE is a associated with accelerated atherosclerosis while serum ferritin and transferrin are strong indicators of SLE activity and damage. Considering the association with MetS and measuring the cIMT in SLE patients is recommended and provides a useful marker for detecting subclinical cases and predicting future cardiovascular events. (C) 2018 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 45 条
[1]  
Abbasi M, 2013, LIFE SCI J, V10
[2]   Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA [J].
Azevedo, George D. ;
Gadelha, Rafael G. N. ;
Vilar, Maria Jose .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (11) :1542-1542
[3]   A review of the metabolic syndrome [J].
Balkau, B. ;
Valensi, P. ;
Eschwege, E. ;
Slama, G. .
DIABETES & METABOLISM, 2007, 33 (06) :405-413
[4]   Hyperhomocysteinemia and metabolic syndrome are risk factors for sub-clinical atherosclerosis in women with systemic lupus erythematosus [J].
Baraka, Eman ;
El Dein, Mounir ;
Farouk, Hesham ;
El Moutaz, Youmna .
EGYPTIAN RHEUMATOLOGIST, 2015, 37 (02) :67-74
[5]   Metabolic syndrome in Argentinean patients with systemic lupus erythematosus [J].
Bellomio, V. ;
Spindler, A. ;
Lucero, E. ;
Berman, A. ;
Sueldo, R. ;
Berman, H. ;
Santana, M. ;
Molina, M. J. ;
Gongora, V. ;
Cassano, G. ;
Paira, S. ;
Saurit, V. ;
Retamozo, G. ;
Alvarellos, A. ;
Caerio, F. ;
Alba, P. ;
Gotero, M. ;
Velozo, E. J. ;
Ceballos, F. ;
Soriano, E. ;
Catoggio, L. ;
Garcia, M. A. ;
Eimon, A. ;
Agueero, S. .
LUPUS, 2009, 18 (11) :1019-1025
[6]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[7]  
Bultink IEM, 2008, CLIN EXP RHEUMATOL, V26, P32
[8]   High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors [J].
Chung, Cecilia P. ;
Avalos, Ingrid ;
Oeser, Annette ;
Gebretsadik, Tebeb ;
Shintani, Ayumi ;
Raggi, Paolo ;
Stein, C. Michael .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) :208-214
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus [J].
Doria, A ;
Shoenfeld, Y ;
Wu, R ;
Gambari, PF ;
Puato, M ;
Ghirardello, A ;
Gilburd, B ;
Corbanese, S ;
Patnaik, M ;
Zampieri, S ;
Peter, JB ;
Favaretto, E ;
Iaccarino, L ;
Sherer, Y ;
Todesco, S ;
Pauletto, P .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1071-1077